
As well as holding the deputy chair position on the board of Orphazyme, Bo Jesper Hansen is something of a celebrity within the treatment of rare diseases, having also co-founded Swedish Orphan Biovitrium, Sobi.
Hansen sold his shares in Swedish Orphan Biovitrium, Sobi in 2016 and stepped down from the board, and has been on the board of Danish biotech company Orphazyme since 2010, observing the development of arimoclomol, which has been submitted to both the FDA and EMA for approval as a treatment for rare metabolic disease Niemann-Pick type C (NPC).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app